ACAT inhibitors for anti-atherosclerosis purpose
|CI976||5.9||2.1||Failed at pre-clinical stage (Parke-Davis)|
|ATR101 (nevanimibe)||0.23||Failed at pre-clinical stage (Parke-Davis)|
|CP113818||0.02||0.02||Failed at pre-clinical stage (Pfizer)|
|CI1011||19||19||Abandoned after phase 3 (Pfizer)|
|CS505 (pactimibe)||4.9||3||Abandoned after phase 3 (Sankyo)|
|K604||0.45||102.9||Abandoned after phase 2 trial (Kowa)|
|F12511||0.039||0.11||Abandoned after phase 1 trial (Lilly)|
TYC and CCYC provided conception and design of the review; TYC wrote the first draft of the manuscript. All other authors were involved in discussing the conception and design of the review, and in collecting key references. All authors read, edited, and approved the submitted version.
The authors declare that they have no conflicts of interest.
This work is supported financially by NIH grant AG AG037609 to TYC and CCYC. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2021.